FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/Novel Peptide Combination Therapy Shows Promise for Alcohol-related Liver Disease
返回研究图书馆

Novel Peptide Combination Therapy Shows Promise for Alcohol-related Liver Disease

November 20, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

Novel Peptide Combination Therapy Shows Promise for Alcohol-related Liver Disease

A recent clinical trial funded by Novo Nordisk A/S has completed its Phase 2 study on the effects of NNC0194-0499, cagrilintide, and semaglutide in treating alcohol-related liver disease. This research, published on ClinicalTrials.gov with identifier NCT06409130, marks a significant step forward in understanding how peptide-based therapies can combat the debilitating effects of liver damage caused by excessive alcohol consumption.

Background

Alcohol-related liver disease (ALD) is one of the leading causes of chronic liver conditions worldwide. It often progresses from fatty liver to alcoholic hepatitis and eventually cirrhosis if left untreated. Current treatment options are limited, making it imperative for researchers to explore innovative therapeutic approaches. Peptide therapy has emerged as a promising avenue due to its targeted action on specific biological pathways involved in liver health.

NNC0194-0499 is an investigational glucagon-like peptide-1 (GLP-1) receptor agonist, while semaglutide is already approved for diabetes management and weight loss. Cagrilintide, another GLP-1 analog, targets appetite suppression to reduce alcohol intake. The combination of these peptides aims to address both the metabolic and behavioral aspects of ALD.

Key Details

The study involved participants with varying stages of alcoholic liver disease who were randomly assigned to receive NNC0194-0499, semaglutide, cagrilintide, or placebo in different combinations. The primary goal was to assess the impact on liver damage and alcohol consumption patterns over a period of approximately 39 weeks.

Researchers monitored participants for changes in liver enzymes, fibrosis markers, and self-reported alcohol use. Preliminary results suggest that the combination therapy may offer significant benefits compared to individual treatments or placebo. However, detailed data analysis is still ongoing to confirm these findings.

Key Takeaways

  • Peptide Synergy: The study highlights the potential of combining different peptides to enhance therapeutic efficacy in treating ALD.
  • Behavioral Impact: Cagrilintide's role in reducing alcohol intake could be crucial for long-term liver health management.
  • Metabolic Benefits: Semaglutide and NNC0194-0499, through their effects on metabolism, may help mitigate the progression of liver damage.
  • Further Research Needed: While promising, more extensive clinical trials are required to establish definitive treatment protocols.

What This Means

For the peptide community, this study underscores the growing importance of peptide-based therapies in managing complex conditions like alcohol-related liver disease. It also emphasizes the need for interdisciplinary research involving clinicians, pharmacologists, and behavioral scientists to develop comprehensive treatment strategies. As more peptides move through clinical trials, regulatory bodies such as the FDA will play a critical role in ensuring these innovative treatments reach those who need them.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。